Appropriate exploitation of these pathways or other well-known pancreas cancer potential molecular targets like KRAS, via a combinatorial, the TME can be leveraged to convert a tumor from ‘non-immunogenic’ to one that may be effectively targeted by immune cells, thereby improving treatments and outcomes for patients with PDAC. Here, KRAS is linked to pancreatic neoplasm.